Notice2023-21459
Foreign-Trade Zone (FTZ) 46, Notification of Proposed Production Activity; Patheon Pharmaceuticals Inc.; (Pharmaceutical Products); Cincinnati, Ohio
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 29, 2023
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 188 (Friday, September 29, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 188 (Friday, September 29, 2023)]
[Notices]
[Pages 67230-67231]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-21459]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-52-2023]
Foreign-Trade Zone (FTZ) 46, Notification of Proposed Production
Activity; Patheon Pharmaceuticals Inc.; (Pharmaceutical Products);
Cincinnati, Ohio
Patheon Pharmaceuticals Inc. (Patheon) submitted a notification of
proposed production activity to the FTZ Board (the Board) for its
facilities in Cincinnati, Ohio, within Subzone 46K. The notification
conforming to the requirements of the Board's regulations (15 CFR
400.22) was received on September 18, 2023.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product(s) and material(s)/component(s) would be added to the
production authority that the Board previously approved for the
operation, as reflected on the Board's website.
The proposed finished product is cancer treatment (active
pharmaceutical ingredient--regorafenib) in finished dosage form (duty-
free).
The proposed material/component is regorafenib active
pharmaceutical ingredient (duty-free). The request indicates that the
material/component is subject to duties under section 301 of the Trade
Act of 1974 (section 301), depending on the country of origin. The
applicable section 301 decisions require subject merchandise to be
admitted to FTZs in privileged foreign status (19 CFR 146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#6402101e2410160500014a030b12"><span class="__cf_email__" data-cfemail="c1a7b5bb81b5b3a0a5a4efa6aeb7">[email protected]</span></a>. The closing period for their receipt is November 8,
2023.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
FOR FURTHER INFORMATION, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#410528202f246f07282f3724330135332025246f262e37"><span class="__cf_email__" data-cfemail="76321f17181358301f1800130436020417121358111900">[email protected]</span></a>.
[[Page 67231]]
Dated: September 26, 2023.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2023-21459 Filed 9-28-23; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 29, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.